Forbion Capital leads $15m series-B for Akarna

Forbion joined existing investors New Science Ventures and Third Point in the round. According to Forbion, the GPs will consider new investments to let the asset grow.

The fresh capital will allow Akarna to develop therapies for the treatment of patients with a progressive form of fatty-liver disease and other fibrotic diseases. The company claims the new treatment will be able to avoid some of the significant side effects associated with other therapies in development.

Company
UK-based Akarna has offices in Cambridge and San Diego. The privately held business develops small molecule therapeutics that target inflammatory and fibrotic diseases for which there is no approved treatment. Akarna does not yet generate revenues and employs a staff of five.

People
Forbion – Marco Boorsma (partner).
Akarna – Raju Mohan (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• Healthcare
• UK / Ireland
• United Kingdom
• Pharmaceuticals
• Venture